Opto-mechanical micro-macro entanglement

We propose to create and detect opto-mechanical entanglement by storing one component of an entangled state of light in a mechanical resonator and then retrieving it. Using micro-macro entanglement of light as recently demonstrated experimentally, one can then create opto-mechanical entangled states where the components of the superposition are macroscopically different. We apply this general approach to two-mode squeezed states where one mode has undergone a large displacement. Based on an analysis of the relevant experimental imperfections, the scheme appears feasible with current technology.Comment: 7 pages, 6 figures, to appear in PRL, submission coordinated with Sekatski et al. who reported on similar result

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: Recent progress and future directions

Several key advances in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) over the past two decades have strategically exploited B-cell lineage markers suitable for targeting by immunotherapies. First, the addition of the anti-CD20 monoclonal antibody (mAb) rituximab to a range of standard therapies conferred remarkable outcomes improvements in diverse settings, perhaps most prominently an overall survival advantage in newly diagnosed diffuse large B-cell lymphoma (DLBCL). Subsequently, multiple chimeric antigen receptor (CAR) T-cell therapies targeting CD19 have revolutionized the treatment of relapsed/refractory (rel/ref) DLBCL and are active in other B-NHL subtypes as well. Most recently, the longstanding aspiration to exploit patients\u27 endogenous T-cells to combat lymphoma has been achieved via T-cell redirecting therapies such as bispecific antibodies (BsAbs) that incorporate dual targeting of a T-cell antigen such as CD3 plus a B-cell antigen such as CD19 or CD20 expressed by the tumor. These novel agents have demonstrated impressive activity as monotherapies in patients with heavily pre-treated, rel/ref B-NHL of a variety of subtypes. Now, myriad clinical trials are exploring combinations of T-cell redirectors with targeted therapies, antibody-drug conjugates, conventional chemotherapy, and even new immunotherapies. Here, we highlight key landmarks in the development of T-cell redirecting therapies for the treatment of B-NHL, emerging evidence and lessons from recent clinical trials, and exciting new directions in this arena

Surface Engineered Angstrom Thick ZnO-sheathed TiO2 Nanowires as Photoanode for Performance Enhanced Dye-sensitized Solar Cells

Cataloged from PDF version of article.This paper presents a systematic study on the effects of angstrom-thick atomic layer deposited (ALD) ZnO sheaths on hydrothermally-grown TiO2 nanowires (NWs) used as photoanodes in dye-sensitized solar cells (DSSCs). We designed, synthesized and characterized the samples prepared using different numbers of ZnO cycles and compared their photovoltaic (PV) performances. The device consisting of TiO2 NWs coated with the optimum thickness (two cycles) of ZnO shell exhibits a three-fold increase in efficiency compared to a control reference device. This paper reports results and features that demonstrate the passivation of surface state traps upon deposition of ZnO shells. While this passivation of surface traps provides a reduction in the back-reactions of the surface state mediated electrons (KET trap), it is speculated that ZnO-induced surface band bending (SBB) substantially reduces the recombination rate of the device by reducing the recombination rate of the conduction band (CB) electrons (KET CB). Moreover, an enhancement in the amount of dye uptake for ZnO-coated TiO2 samples is observed and explained with the isoelectric point (IEP) concept. In spite of the excellent PV power conversion efficiencies achieved by the first ZnO cycles, thicker layers impede the electron injection rate, reducing the efficiency of the device by capturing the photogenerated dye electrons in ZnO quantum wells. Here, we investigate the mechanisms contributing to this unprecedented change and correlate them with the enhancement in device efficiency. © The Royal Society of Chemistry 2014

Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States

Axicabtagene ciloleucel (axi-cel) is a standard-of-care for patients with relapsed or refractory (r/r) large B cell lymphoma who have received 2 or more lines of prior therapy. Patients receiving axi-cel in the real world could have broader a demographic, disease, and treatment profile compared with that of the cohort in the pivotal ZUMA-1 trial. The present study was conducted to evaluate the outcomes of axi-cel therapy in the real-world setting. A total of 1297 patients receiving commercial axi-cel between 2017 and 2020 were selected from the Center for International Blood and Marrow Transplant Research\u27s data registry, of whom 739 (57%) would have been ineligible for inclusion in the ZUMA-1 cohort. Efficacy and safety outcomes were described for the entire cohort and by ZUMA-1 eligibility. Their associations with age, Eastern Cooperative Oncology Group Performance Score, and comorbidities were evaluated using multivariable logistic and Cox regressions. At a median follow-up of 12.9 months, the overall response rate (ORR) was 73%, with a 56% complete response (CR) rate. Median overall survival (OS) and progression-free survival (PFS) were 21.8 months (95% confidence interval [CI], 17.4 to 28.8 months) and 8.6 months (95% CI, 6.5 to 12.1 months), respectively. Duration of response (DOR) was comparable in the ZUMA-1 ineligible patients and ZUMA-1 eligible patients (62% by 1 year [95% CI, 57% to 66%] versus 67% [95% CI, 62% to 72%]). Patients age ≥65 years had favorable ORR (odds ratio [OR], 1.39; 95% CI, 1.05 to 1.83) despite having a higher risk of cytokine release syndrome (CRS) (OR, 1.41; 95% CI, 1.02 to 1.94) and immune effector cell-associated neurotoxicity syndrome (ICANS) (OR, 1.77; 95% CI, 1.39-2.26). Eastern Cooperative Oncology Group Performance Score ≥2 was associated with inferior efficacy outcomes (OR for ORR, 0.32; 95% CI, 0.18-0.56; hazard ratio [HR] for OS, 3.27; 95% CI, 2.37 to 4.52) and higher incidence of ICANS (OR, 2.63; 95% CI, 1.40 to 4.93). The patients ineligible for ZUMA-1 still had a durable response with axi-cel. Elderly patients had favorable efficacy outcomes despite higher rates of CRS and ICANS. Patient selection for standard-of-care axi-cel should consider comorbidities and risk-to-benefit ratio rather than be based strictly on ZUMA-1 eligibility

Complementary spiral resonators for ultrawideband suppression of simultaneous switching noise in high-speed circuits

Cataloged from PDF version of article.In this paper, a novel concept for ultra-wideband simultaneous switching noise (SSN) mitigation in high-speed printed circuit boards (PCBs) is proposed. Using complementary spiral resonators (CSRs) etched on only a single layer of the power plane and cascaded co-centrically around the noise port, ultra-wideband SSN suppression by 30 dB is achieved in a frequency span ranging from 340 MHz to beyond 10 GHz. By placing a slit in the co-centric rings, lower cut-off frequency is reduced to 150 MHz, keeping the rest of the structure unaltered. Finally, the power plane structure with modified complementary spiral resonators (MCSRs) is designed, fabricated, and evaluated experimentally. Measurement and simulation results are in well-agreement